A cross-sectional evaluation of the idiopathic pulmonary fibrosis patient satisfaction and quality of life with a care coordinator.

Idiopathic pulmonary fibrosis (IPF) quality of life satisfaction

Journal

Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 8 2 2020
pubmed: 8 2 2020
medline: 8 2 2020
Statut: ppublish

Résumé

Canadian and international guidelines recommend specialized, multidisciplinary teams for the treatment of patients with idiopathic pulmonary fibrosis (IPF). The objective of this cross-sectional clinical study was to investigate the effect of a care coordinator on IPF patient satisfaction and quality of life. Forty IPF patients were enrolled from the practices of two physicians (n=20/physician), with either low (LCU) or high-coordinator use (HCU). Patient satisfaction was measured with modified FAMCARE and IPF Care UK Patient Support Program (UK-CARE) surveys. Health related quality of life (HRQoL) was assessed with the living with IPF impacts (L-IPFi) survey. An economic model assessed the impact of the coordinator; staff surveys informed patient management requirements, and costs were derived from published literature. Patient satisfaction was similar between the clinics; a trend (P=0.1) towards increased satisfaction among HCU patients was observed. Patients in the HCU clinic reported increased satisfaction (P<0.05) with their current care compared with care prior to joining the tertiary-care clinic, while LCU patients did not. IPF patient HRQoL did not differ between clinics. The coordinator was estimated to alleviate approximately 30% of a physician's IPF-related work load, and to facilitate the care of more patients per physician. Modelled estimates suggest the coordinator lead to annual cost-savings of $137,212. Reliance upon a coordinator during routine management of IPF patients may improve patient satisfaction, spare physician time and lead to annual cost-savings. Future studies should examine the impact of a coordinator on healthcare resource utilization.

Sections du résumé

BACKGROUND BACKGROUND
Canadian and international guidelines recommend specialized, multidisciplinary teams for the treatment of patients with idiopathic pulmonary fibrosis (IPF). The objective of this cross-sectional clinical study was to investigate the effect of a care coordinator on IPF patient satisfaction and quality of life.
METHODS METHODS
Forty IPF patients were enrolled from the practices of two physicians (n=20/physician), with either low (LCU) or high-coordinator use (HCU). Patient satisfaction was measured with modified FAMCARE and IPF Care UK Patient Support Program (UK-CARE) surveys. Health related quality of life (HRQoL) was assessed with the living with IPF impacts (L-IPFi) survey. An economic model assessed the impact of the coordinator; staff surveys informed patient management requirements, and costs were derived from published literature.
RESULTS RESULTS
Patient satisfaction was similar between the clinics; a trend (P=0.1) towards increased satisfaction among HCU patients was observed. Patients in the HCU clinic reported increased satisfaction (P<0.05) with their current care compared with care prior to joining the tertiary-care clinic, while LCU patients did not. IPF patient HRQoL did not differ between clinics. The coordinator was estimated to alleviate approximately 30% of a physician's IPF-related work load, and to facilitate the care of more patients per physician. Modelled estimates suggest the coordinator lead to annual cost-savings of $137,212.
CONCLUSIONS CONCLUSIONS
Reliance upon a coordinator during routine management of IPF patients may improve patient satisfaction, spare physician time and lead to annual cost-savings. Future studies should examine the impact of a coordinator on healthcare resource utilization.

Identifiants

pubmed: 32030274
doi: 10.21037/jtd.2019.11.41
pii: jtd-11-12-5547
pmc: PMC6988068
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5547-5556

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

2019 Journal of Thoracic Disease. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: Daniel Grima, Daniel Moldaver and Margaret Ainslie-Garcia are employees of Cornerstone Research Group. Diana Fung, Czerysh Cabalteja and Patricia DeMarco are employees of Hoffmann-La Roche. Hoffmann-La Roche contracted Cornerstone Research Group to oversee and analyze the conduct of this study. Gerard Cox has received personal fees from Boston Scientific. Nathan Hambly has received honoraria and awarded grants from Actelion, Bayer, Boehringer Ingelheim, Novartis, and Roche. Martin Kolb has received honoraria, awarded grants or consulting fees from Roche, Boehringer Ingelheim, GSK, Gilead, Actelion, Respivert, Alkermes, Pharmaxis, Prometic, Indalo and Third Pole. The other authors have no conflicts of interest to declare.

Références

Eur Respir Rev. 2018 Feb 7;27(147):null
pubmed: 29436402
Support Care Cancer. 2016 Sep;24(9):3821-30
pubmed: 27067593
BMC Pulm Med. 2016 Jan 14;16:10
pubmed: 26762154
Adv Ther. 2015 Feb;32(2):87-107
pubmed: 25691376
Br J Dermatol. 2011 Sep;165(3):600-11
pubmed: 21692770
Eur Respir J. 2016 Jul;48(1):187-95
pubmed: 27230442
Int J Chron Obstruct Pulmon Dis. 2013;8:209-14
pubmed: 23641152
Am J Hosp Palliat Care. 2017 Aug;34(7):597-602
pubmed: 27103067
Heart Lung. 2010 Jul-Aug;39(4):304-13
pubmed: 20561836
Popul Health Manag. 2011 Jun;14(3):133-6
pubmed: 21214417
Expert Rev Respir Med. 2014 Apr;8(2):173-8
pubmed: 24450476
Dtsch Arztebl Int. 2016 Jun 17;113(24):415-21
pubmed: 27380757
Eur J Cancer. 2009 Dec;45(18):3182-8
pubmed: 19786345
Int J Behav Med. 2016 Feb;23(1):1-11
pubmed: 25920707
J Adv Nurs. 2012 Jun;68(6):1224-34
pubmed: 22004474
Neurocrit Care. 2008;9(3):287-92
pubmed: 18196476
J Adv Nurs. 2015 May;71(5):1055-65
pubmed: 25533573
Crit Care Nurs Q. 2016 Oct-Dec;39(4):335-44
pubmed: 27575796

Auteurs

Nathan Hambly (N)

Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Sarah Goodwin (S)

Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.

Afia Aziz-Ur-Rehman (A)

Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.

Nima Makhdami (N)

Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.

Margaret Ainslie-Garcia (M)

Cornerstone Research Group, Burlington, Ontario, Canada.

Daniel Grima (D)

Cornerstone Research Group, Burlington, Ontario, Canada.

Gerard Cox (G)

Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Martin Kolb (M)

Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Diana Fung (D)

Department of Medical Affairs, Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.

Czerysh Cabalteja (C)

Department of Medical Affairs, Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.

Patricia DeMarco (P)

Department of Medical Affairs, Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.

Daniel Moldaver (D)

Cornerstone Research Group, Burlington, Ontario, Canada.

Classifications MeSH